TARS Tarsus Pharmaceuticals, Inc.
72.22USD-1.89%Mkt Cap: 3.38B $P/E: —Today
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotil…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap3.38B USD
Enterprise Value2.89B USD
Revenue (TTM)606.33M USD
Gross Profit420.68M USD
Net Income (TTM)-66.42M USD
Revenue/Share14.12 USD
Last Price72.22 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees370
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-205.86
PEG—
EV/EBITDA-62.59
EV/Revenue4.77
P/S5.72
P/B9.25
EPS (TTM)-1.08
EPS (Forward)-0.36
52W Range
53.8949% of range91.53
52W High91.53 USD
52W Low53.89 USD
Profitability
Gross Margin93.20%
Oper. Margin-11.45%
EBITDA Margin-7.62%
Profit Margin-14.72%
ROE-19.34%
ROA-11.81%
Growth
Revenue Growth69.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.45M USD
CapEx (TTM)9.86M USD
FCF Margin11.13%
FCF Yield2.00%
Net Debt-360.88M USD
Net Debt/EBITDA7.81
Balance Sheet
Debt/Equity0.21
Current Ratio3.20
Quick Ratio3.12
Book Value/Sh8.01 USD
Cash/Share10.25 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)99.50 USD
Upside (mean)+37.8%
Target Range84.00 USD – 116.00 USD
84.00+37.8% to mean116.00
# Analysts10
Ownership
Shares Out.46.79M
Float32.74M
Insiders2.69%
Institutions99.93%
Short Interest
Short Ratio7.9d
Short % Float13.50%
Short % Out.13.10%
Shares Short6.13M
Short (prev mo.)6.00M
Technical
SMA 5072.74 (-0.7%)
SMA 20068.52 (+5.4%)
Beta0.45
S&P 52W Chg16.45%
Avg Vol (30d)710.77K
Avg Vol (10d)918.89K
Technical Indicators
RSI (14)43.9
MACD0.0706
MACD Signal1.1135
MACD Hist.-1.0428
BB Upper84.50 USD
BB Middle77.23 USD
BB Lower69.97 USD
BB Width18.82%
ATR (14)2.995 USD
Vol Ratio (20d)0.76x